Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
7.74
-0.19 (-2.40%)
At close: Nov 20, 2026, 4:00 PM EST
8.16
+0.42 (5.43%)
After-hours: Nov 20, 2026, 7:56 PM EST
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Moleculin Biotech the 38,803rd largest employer in the world and 5,598th in the United States.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$509,294
Market Cap
7.54M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - | 17 | 0 |
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Vistagen Therapeutics | 41 |
| Kyntra Bio | 34 |
| Lisata Therapeutics | 21 |
| IN8bio | 20 |
| CalciMedica | 12 |
| Ensysce Biosciences | 10 |
| Immuron | 8 |
MBRX News
- 2 days ago - Moleculin Biotech trading resumes - TheFly
- 2 days ago - Moleculin Biotech trading halted, volatility trading pause - TheFly
- 3 days ago - Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance - GlobeNewsWire
- 5 days ago - Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout - GlobeNewsWire
- 8 days ago - Moleculin Biotech Quarterly report: Q3 2026 - Filings
- 8 days ago - Moleculin Biotech Earnings release: Q3 2026 - Filings
- 9 days ago - Moleculin granted Australian patent covering preliposomal Annamycin lyophilizate - TheFly
- 9 days ago - Moleculin Secures Australian Patent for Annamycin Formulation Technology - GlobeNewsWire